Form 4: KKR Sells 6 Million Shares of BridgeBio Pharma (BBIO) in Block Trade

KKR Genetic Disorder L.P. sold 6 million shares of BridgeBio Pharma at $34.20 per share.

Summary

• KKR Genetic Disorder L.P. sold 6,000,000 shares of BridgeBio Pharma, Inc. (BBIO) common stock.
• The sale occurred on May 12, 2025, at a price of $34.20 per share.
• The transaction was executed as a block sale pursuant to Rule 144 of the Securities Act of 1933.
• Following the transaction, KKR Genetic Disorder L.P. indirectly beneficially owns 13,260,971 shares.
• Several KKR entities and individuals, including KKR Genetic Disorder GP LLC, KKR Group Partnership L.P., KKR Group Holdings Corp., KKR Group Co. Inc., KKR & Co. Inc., KKR Management LLP, Henry R. Kravis, and George R. Roberts, are listed as reporting persons.
• These reporting persons disclaim beneficial ownership of the reported securities, except to the extent of their pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard SEC filing related to a share sale. The sale itself doesn't inherently indicate positive or negative sentiment towards the company's future.

Industry Context

Block trades by major shareholders are common and can create short-term price volatility but don't necessarily reflect a change in the company's long-term prospects.

Stakeholder Impact

• The sale of a large block of shares could potentially create short-term price volatility for shareholders.
• The transaction does not appear to directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

BridgeBio Pharma, BBIO, KKR, Genetic Disorder L.P., Share Sale, Block Trade, Rule 144, Beneficial Ownership, Securities Exchange Act